iBio Raises $46.5M, Advances Obesity Pipeline with AI-Driven Antibodies

TL;DR

**IBIO is a high-risk, high-reward bet on AI-driven obesity drugs, but they're burning cash and clinical trials are still years away.**

AI Summary

iBio, Inc. (IBIO) is a preclinical stage biotechnology company focused on developing precision antibodies for cardiometabolic and obesity treatments, leveraging its AI Drug Discovery Platform. For the fiscal year ended June 30, 2025, the company made significant preclinical progress, including advancing IBIO-610 (an Activin E antibody) to development candidate selection, advancing a Myostatin Activin A bispecific antibody to in vitro proof of concept, and progressing IBIO-600 (a long-acting anti-myostatin antibody) into IND-enabling studies. The company also expanded its collaboration with AstralBio, Inc. and in-licensed IBIO-600 and IBIO-610. Financially, iBio completed an underwritten public offering on August 22, 2025, generating approximately $46.5 million in net proceeds, and a warrant inducement transaction on April 29, 2025, yielding approximately $6.2 million in gross proceeds. The company anticipates commencing its first human clinical trials in late fiscal 2026 or early fiscal 2027.

Why It Matters

iBio's focus on next-generation obesity therapies, particularly those addressing muscle loss and fat regain post-GLP-1 treatment, positions it in a highly competitive and rapidly expanding market. Success in developing differentiated molecules like IBIO-610 and IBIO-600 could offer significant value to investors by capturing a share of the multi-billion dollar obesity drug market, potentially improving patient outcomes beyond current GLP-1 limitations. For employees, this signals a period of intense R&D and potential growth, while customers could benefit from more effective and durable weight management solutions. The strategic use of AI in drug discovery could also set a new competitive standard in the biotech industry.

Risk Assessment

Risk Level: high — iBio is a preclinical stage biotechnology company with no products in human clinical trials, indicating a high inherent development risk. The company's reliance on future clinical success, anticipated in late fiscal 2026 or early fiscal 2027, means significant time and capital are required before potential revenue generation. Furthermore, while recent financing raised $46.5 million, the company's ongoing R&D expenses and the need for further funding if Series G and H warrants are not fully exercised for cash, present substantial financial risk.

Analyst Insight

Investors should approach IBIO with extreme caution, recognizing its preclinical stage and the long, uncertain path to market. While the AI platform and focus on obesity are compelling, consider this a highly speculative investment. Monitor progress on IND-enabling studies for IBIO-600 and the planned commencement of human clinical trials in late fiscal 2026 or early fiscal 2027 as key milestones, but be aware of the significant dilution risk from future capital raises.

Financial Highlights

debt To Equity

Not Disclosed

revenue

Not Disclosed

operating Margin

Not Disclosed

total Assets

Not Disclosed

total Debt

Not Disclosed

net Income

Not Disclosed

eps

Not Disclosed

gross Margin

Not Disclosed

cash Position

Not Disclosed

revenue Growth

Not Disclosed

Key Numbers

• $22,429,069 — Aggregate market value of common equity held by non-affiliates (as of December 31, 2024, based on $2.45 per share)
• 19,654,636 — Shares of common stock issued and outstanding (as of September 4, 2025)
• $46.5 million — Net proceeds from 2025 Underwritten Public Offering (received on August 22, 2025, after deducting underwriting discounts and offering expenses)
• $50 million — Additional gross proceeds potential (if Series G Warrants and Series H Warrants are exercised in full for cash)
• $6.2 million — Aggregate gross proceeds from warrant inducement transaction (received on April 29, 2025, from exercise of Existing Warrants and sale of Inducement Warrants)
• 71,540,000 — Pre-funded warrants issued in 2025 Offering (to purchase shares of common stock)
• 5,626,685 — Existing Warrants exercised for cash (on April 29, 2025, at a reduced exercise price of $0.86 per share)
• 11,253,370 — Inducement Warrants issued (to purchase shares of common stock for $0.125 per warrant)
• 8.9% — Reduction in body weight by IBIO-610 monotherapy (in a DIO mouse model compared to baseline and placebo)
• 26% — Reduction in fat mass by IBIO-610 monotherapy (in a DIO mouse model with no measurable loss of lean mass)

Key Players & Entities

• iBio, Inc. (company) — registrant
• AstralBio, Inc. (company) — discovery collaboration partner and licensor
• Leerink Partners LLC (company) — underwriter for 2025 Offering
• Nasdaq Stock Market LLC (regulator) — exchange where common stock is registered
• SEC (regulator) — Securities and Exchange Commission
• IBIO-610 (company) — Activin E antibody development candidate
• IBIO-600 (company) — long-acting anti-myostatin antibody in IND-enabling studies
• Activin E (company) — therapeutic target for IBIO-610
• Myostatin (company) — therapeutic target for IBIO-600 and bispecific antibody
• Activin A (company) — therapeutic target for bispecific antibody

FAQ

Risk Factors

• Financing Risks [high — financial]: The Company has historically incurred significant operating losses and expects to continue to incur losses for the foreseeable future. It may require substantial additional capital to fund its ongoing operations and development activities. Failure to secure additional financing on acceptable terms could limit its ability to develop or commercialize its product candidates, which would have a material adverse effect on its business, financial condition, and results of operations.
• Drug Development and Regulatory Approval [high — regulatory]: The development of pharmaceutical products is a lengthy, expensive and uncertain process. The Company's product candidates must undergo rigorous preclinical and clinical testing and regulatory review before they can be approved for marketing. There is no guarantee that any of its product candidates will successfully complete clinical trials or receive regulatory approval.
• Competition [high — market]: The biotechnology industry is highly competitive. The Company faces competition from large pharmaceutical companies and biotechnology companies, many of which have greater financial resources, established drug discovery and development capabilities, and experience in obtaining regulatory approvals and marketing products. The market for obesity and cardiometabolic treatments is particularly competitive.
• Reliance on Key Personnel [medium — operational]: The Company's success depends on its ability to attract and retain highly qualified scientific, technical and management personnel. The loss of key personnel could adversely affect its ability to conduct research and development, manage its business and achieve its strategic objectives.
• Third-Party Manufacturing [medium — operational]: The Company relies on third-party manufacturers to produce its product candidates. Any disruption in the supply chain or inability of these manufacturers to meet quality and quantity requirements could delay or prevent the commercialization of its products.
• Intellectual Property [medium — legal]: The Company's ability to protect its intellectual property is critical. It relies on patents, trade secrets and other proprietary rights to protect its discoveries. The failure to obtain or maintain adequate patent protection could allow competitors to develop or commercialize similar products.
• Stock Price Volatility [medium — financial]: The Company's stock price has been and may continue to be subject to significant volatility due to factors such as the progress of its clinical trials, regulatory approvals, financing activities, and general market conditions. This volatility could adversely affect the ability to raise capital and the value of its stock.
• Cybersecurity Risks [low — cybersecurity]: The Company's information systems are vulnerable to cyberattacks and security breaches. A significant cybersecurity incident could disrupt operations, compromise sensitive data, and result in financial losses and reputational damage.

Industry Context

iBio operates in the highly competitive biotechnology sector, specifically focusing on the rapidly evolving obesity and cardiometabolic therapeutic space. The market has seen significant advancements with the introduction of GLP-1 receptor agonists, creating a demand for next-generation therapies that address limitations such as muscle loss and fat regain. iBio aims to leverage its AI Drug Discovery Platform to develop differentiated antibody therapeutics that offer improved efficacy and tolerability compared to existing treatments.

Regulatory Implications

As a preclinical biotechnology company, iBio faces significant regulatory hurdles. Its product candidates must successfully navigate rigorous preclinical testing and subsequent clinical trials to gain approval from regulatory bodies like the FDA. Delays or failures in the regulatory process, or the inability to meet stringent safety and efficacy standards, could materially impact the Company's ability to bring its therapies to market.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]
4. [object Object]

Key Dates

• 2025-08-22: Completed Underwritten Public Offering — Generated approximately $46.5 million in net proceeds, strengthening the Company's financial position to fund ongoing development.
• 2025-04-29: Warrant Inducement Transaction — Yielded approximately $6.2 million in gross proceeds, providing additional capital for operations.
• 2025-06-30: Fiscal Year End — Marks the end of the reporting period for the 10-K filing, summarizing the Company's performance and financial status.
• 2026-12-31: Late Fiscal 2026 — Anticipated commencement of the Company's first human clinical trials, a critical milestone for advancing its product candidates.
• 2027-06-30: Early Fiscal 2027 — Anticipated commencement of the Company's first human clinical trials, a critical milestone for advancing its product candidates.

Glossary

Preclinical Stage

The stage of drug development that occurs before human testing, involving laboratory and animal studies to assess safety and efficacy. (Indicates that iBio's product candidates are in the early stages of development and have not yet been tested in humans.)

AI Drug Discovery Platform

A proprietary system that uses artificial intelligence and machine learning to identify and design potential drug molecules. (This is iBio's core technology for developing its precision antibodies, aiming to accelerate the discovery process and identify novel biologics.)

Activin E antibody

A therapeutic antibody designed to target and inhibit the function of Activin E, a protein involved in various biological processes. (Represents a specific product candidate (IBIO-610) in iBio's pipeline, aimed at cardiometabolic and obesity treatments.)

Myostatin Activin A bispecific antibody

An antibody engineered to target both Myostatin and Activin A simultaneously, potentially offering enhanced therapeutic effects. (Another key development in iBio's pipeline, indicating a strategy to address multiple targets for improved efficacy in obesity and muscle-related conditions.)

IND-enabling studies

Studies required by regulatory authorities (like the FDA) to be completed before a drug can be tested in humans, typically including toxicology and pharmacology studies. (Shows that IBIO-600 is progressing towards the critical step of seeking approval for human clinical trials.)

GLP-1 receptor agonists

A class of drugs that mimic the effects of the GLP-1 hormone, commonly used to treat type 2 diabetes and obesity. (iBio's precision antibodies are positioned as next-generation therapies to address limitations of current GLP-1 treatments, such as muscle loss and fat regain.)

DIO mouse model

Diet-induced obesity mouse model, a common animal model used to study obesity and test potential anti-obesity treatments. (Provides context for the preclinical efficacy data of IBIO-610, showing an 8.9% reduction in body weight and 26% reduction in fat mass.)

Underwritten Public Offering

A type of public offering where an investment bank (underwriter) purchases securities from the issuer and resells them to the public. (Indicates a significant financing event for iBio, raising $46.5 million in net proceeds to fund its operations and development.)

Year-Over-Year Comparison

The fiscal year ended June 30, 2025, shows significant preclinical progress for iBio, Inc., with key candidates advancing. Financially, the Company bolstered its position through a substantial public offering in August 2025, raising approximately $46.5 million in net proceeds, indicating a focus on funding development. While specific year-over-year financial metrics like revenue and net income are not detailed in this excerpt, the emphasis on R&D advancements and capital raises suggests a strategic shift towards pipeline development and de-risking for future clinical stages.

Key Financial Figures

• $2.45 — 4, based upon the closing sale price of $2.45 per share reported as of December 31, 2
• $0.699 — t and accompanying Series G Warrant was $0.699. The closing of the 2025 Offering took
• $46.5 million — from the 2025 Offering of approximately $46.5 million after deducting underwriting discounts
• $50 million — may also receive up to an aggregate of $50 million of additional gross proceeds if the Ser
• $0.86 — on Stock at a reduced exercise price of $0.86 per share, which was the Minimum Price,
• $0.125 — Warrant Shares"), for consideration of $0.125 per Inducement Warrant. We received agg
• $6.2 million — gregate gross proceeds of approximately $6.2 million from the exercise of the Existing Warra

Filing Documents

• ibio-20250630x10k.htm (10-K) — 2988KB
• ibio-20250630xex4d2.htm (EX-4.2) — 18KB
• ibio-20250630xex4d15.htm (EX-4.15) — 121KB
• ibio-20250630xex10d81.htm (EX-10.81) — 91KB
• ibio-20250630xex10d82.htm (EX-10.82) — 90KB
• ibio-20250630xex23d1.htm (EX-23.1) — 6KB
• ibio-20250630xex31d1.htm (EX-31.1) — 20KB
• ibio-20250630xex31d2.htm (EX-31.2) — 20KB
• ibio-20250630xex32d1.htm (EX-32.1) — 9KB
• ibio-20250630xex32d2.htm (EX-32.2) — 8KB
• ibio-20250630x10k001.jpg (GRAPHIC) — 27KB
• ibio-20250630x10k002.jpg (GRAPHIC) — 61KB
• ibio-20250630x10k003.jpg (GRAPHIC) — 89KB
• ibio-20250630x10k004.jpg (GRAPHIC) — 70KB
• ibio-20250630x10k005.jpg (GRAPHIC) — 26KB
• ibio-20250630x10k006.jpg (GRAPHIC) — 62KB
• ibio-20250630x10k007.jpg (GRAPHIC) — 92KB
• ibio-20250630x10k008.jpg (GRAPHIC) — 73KB
• ibio-20250630x10k009.jpg (GRAPHIC) — 47KB
• ibio-20250630x10k010.jpg (GRAPHIC) — 67KB
• ibio-20250630x10k011.jpg (GRAPHIC) — 57KB
• 0001558370-25-011888.txt ( ) — 15795KB
• ibio-20250630.xsd (EX-101.SCH) — 89KB
• ibio-20250630_cal.xml (EX-101.CAL) — 82KB
• ibio-20250630_def.xml (EX-101.DEF) — 526KB
• ibio-20250630_lab.xml (EX-101.LAB) — 721KB
• ibio-20250630_pre.xml (EX-101.PRE) — 788KB
• ibio-20250630x10k_htm.xml (XML) — 2260KB

Business

Business 1 Item 1A.

Risk Factors

Risk Factors 34 Item 1B. Unresolved Staff Comments 70 Item 1C. Cybersecurity 70 Item 2.

Properties

Properties 70 Item 3.

Legal Proceedings

Legal Proceedings 71 Item 4. Mine Safety Disclosures 71 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 72 Item 6. [Reserved] 72 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 72 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 81 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 81 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 81 Item 9A.

Controls and Procedures

Controls and Procedures 81 Item 9B. Other Information 82 Item 9C Disclosure Regarding Foreign Jurisdictions That Prevent Inspections 83 PART III Item 10. Directors, Executive Officers and Corporate Governance 84 Item 11.

Executive Compensation

Executive Compensation 84 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 84 Item 13. Certain Relationships and Related Transactions, and Director Independence 84 Item 14. Principal Accountant Fees and Services 85 PART IV Item 15. Exhibits and Financial Statement Schedules 86 Item 16. Form 10-K Summary 86 Table of Contents SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS Unless the context requires otherwise, references in this Annual Report for the fiscal year ended June 30, 2025 (this "Annual Report") to "iBio," the "Company," "we," "us," "our" and similar terms mean iBio, Inc. Certain statements in this Annual Report, including, without limitation, statements under the heading "Management's Discussion and Analysis of Financial Condition and Results of Operations," include forward-looking statements as defined in Section 27A of the Securities Act of 1933 (the "Securities Act"), Section 21E of the Securities Exchange Act of 1934 (the "Exchange Act"), the Private Securities Litigation Reform Act of 1995 (the "PSLRA") or in releases made by the Securities and Exchange Commission (the "SEC"), all as may be amended from time to time. These cautionary statements are being made pursuant to the Securities Act, the Exchange Act and the PSLRA with the intention of obtaining the benefits of the "safe harbor" provisions of such laws. All statements contained in this Annual Report, other than statements that are purely historical, are forward-looking statements. Forward looking-statements can be identified by, among other things, the use of forward-looking language, such as the words "plans," "intends," "believes," "expects," "anticipates," "estimates," "projects," "potential," "may," "will," "would," "could," "should," "seeks," or "scheduled to," or other similar words, the negative of these terms, other variations of these terms or comparable language, or by discussion of strategy or intentions. Forward-looking statements a

Business

Item 1. Business. Overview iBio, Inc. (also referred to as "we", "us", "our", "iBio", or the "Company") is a preclinical stage biotechnology company leveraging the power of Artificial Intelligence ("AI") for the development of hard-to-drug precision antibodies in the cardiometabolic and obesity space. Our core mission is to harness the potential of AI and machine learning ("ML") to unveil novel biologics which other scientists have been unable to develop. Through our innovative AI Drug Discovery Platform, we have been able to identify differentiated molecules aimed to address unmet needs by current glucagon-like peptide-1 ("GLP-1") receptor agonists. We believe the future of obesity care lies not just in weight loss—but in quality weight loss. Current interventional therapies such as GLP-1 receptor agonists have ushered in a breakthrough era, yet challenges remain: muscle loss, fat regain after treatment cessation, and long-term tolerability. We are developing second-generation therapies to meet these unmet needs, using the power of AI-guided antibody design and advanced screening technologies. Our obesity strategy is built on three key principles. First, we are aiming to develop next-generation antibody therapeutics addressing limitations of current approved treatments, offering options with a goal to preserve muscle mass, target fat selectively, and provide durable weight loss with improved tolerability. Second, we are focusing on targets with strong human validation, which we believe both helps reduce development risk and increase the likelihood of clinical success. Lastly, we are applying our integrated AI Drug Discovery Platform and deep scientific expertise to rapidly generate development-ready biologics, enabling us to move with speed and precision in a competitive and fast-evolving field. We anticipate the commencement of our first human clinical trials in late fiscal 2026 or early fiscal 2027. As we continue to leverage our technology stack and develop